.Competing rate of interests.R.S., M.S., H.G. and also A.A.R. are actually planners of the 1M1M project. H.G. and also A.A.R. are actually board of supervisors participants as well as R.S., M.S. and A.A.R. are actually participants of the clinical advisory committee of N1C. A.A.R. makes known employment through LUMC, which possesses patents on exon-skipping technology, a few of which has actually been actually certified to BioMarin and consequently sublicensed to Sarepta. As co-inventor of a few of these licenses, A.A.R. was allowed to an allotment of royalties. A.A.R. better makes known acting as impromptu professional for PTC Rehabs, Sarepta Therapies, Regenxbio, Dyne Therapies, Lilly, BioMarin Pharmaceuticals Inc., Eisai, Entrada, Takeda, Splicesense, Galapagos, Sapreme, Italfarmaco and Astra Zeneca. Before 5 years, A.A.R. likewise conducted consulting with for Alpha Anomeric. A.A.R. also discloses membership of the medical boards of advisers of Eisai, Hybridize Therapies, Muteness Therapeutics, Sarepta Therapies, Sapreme and also Mitorx. Over the last 5 years, A.A.R. was likewise a clinical advisory board participant for ProQR. Wage for A.A.R. u00e2 s consulting and advising tasks is paid to LUMC. In the past 5 years, LUMC also received sound speaker gratuity from PTC Therapies, Alnylam Netherlands, Italfarmaco as well as Pfizer and also financing for agreement investigation from Sapreme, Eisai, Galapagos, Synaffix and Alpha Anomeric. Project funding is actually received from Sarepta Therapeutics and also Entrada by means of unlimited grants. H.G. possesses nothing at all to disclose in relation to the subjects covered within this composition. Previously 5 years, he has actually likewise acquired consultancy gratuity coming from UCB. M.S. obtained working as a consultant honoraria coming from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly and also Solaxa before 5 years, all unconnected to the present document. R.S. has nothing to disclose in regard to the subjects dealt with in this manuscript. She has obtained speaker and/or working as a consultant gratuity or even financing payments coming from Abbvie, Bial, STADA as well as Everpharma previously 5 years.